Table 1.

Associations between nuclear area, percentages of ploidy, proliferation, DNA-hypomethylation and clinicopathological features.

	n	Nuclear Area			Hyperploidy (%)			Aneuploidy (%)			Proliferation index			Chr1 Sat2 hypomethylation			Chr1 Satα hypomethylation			LINE1 DNA-Hypomethylation
Variable		≤median (n=35)	>median	P	≤median (n=35)	>median (n=35)	P	≤median (n=35)	>median (n=35)	P	≤median (n=35)	>median (n=35)	P	≤Score 2 (n=49)	>Score 2 (n=21)	P	≤Score 2 (n=44)	>Score 2 (n=24)	P	≤median (n=35)	>median (n=35)	P
Age
< 60 yrs.	29	16	13	0.467	14	15	0.808	20	9	0.008	14	15	0.81	23	6	0.153	17	11	0.564	19	10	0.029
> 60 yrs.	41	19	22		21	20		15	26		21	20		26	15		27	13		16	25
FIGO
I/II	16	11	5	0.088	8	8	n.a	8	8	n.a	10	6	0.26	14	2	0.820	14	1	0.020	11	5	0.088
III/IV	54	24	30		27	27		27	27		25	29		35	19		30	23		24	30
Tumor grade
I/II	49	27	22	0.192	22	27	0.192	25	24	0.79	25	24	0.79	35	14	0.690	32	16	0.600	27	22	0.192
III	21	8	13		13	8		10	11		10	11		14	7		12	8		8	13
Histology
Serous cancer	33	20	13	0.075	19	14	0.488	19	14	0.488	20	13	0.243	21	12	0.270	18	15	0.092	17	16	0.917
Mucinous cancer	30	14	16		13	17		13	17		12	18		24	6		23	6		15	15
Endometrioid cancer	7	1	6		3	4		3	4		3	4		4	3		3	3		3	4
Residual disease after surgery
No residual disease	27	14	13	0.880	14	13	0.555	12	15	0.759	16	11	0.054	21	6	0.486	19	7	0.474	15	12	0.759
Residual disease≤2 cm	19	10	9		11	8		10	9		5	14		13	6		12	7		9	10
Residual disease>2 cm	24	11	13		10	14		13	11		14	10		15	9		13	10		11	13

Note: Samples with satellite hypomethylation scores of ≤2 had no, slight or only moderate, samples with satellite hypomethylation scores of >2 had much hypomethylation. The significance level (P) was determined by the Chi²-Statistic.